Volume 26, Issue 2 (3-2022)                   ibj 2022, 26(2): 160-174 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dariushnejad H, Ghorbanzadeh V, Akbari S, Hashemzadeh P. Design of a Novel Recombinant Multi-epitope Vaccine against Triple Negative Breast Cancer. ibj. 2022; 26 (2) :160-174
URL: http://ibj.pasteur.ac.ir/article-1-3447-en.html
BACKGROUNDː Triple-negative breast cancer (TNBC) determined by absence of expression ERBB2, estrogen and progesterone receptors. Breast cancer novel vaccines are revealed as the forthcoming of advanced stage TNBC therapeutic. The aim of this study was to evaluate Carcinoembryonic antigen (CEA), Metadherin (MTDH) and MUC-1 (Mucin 1) proteins as vaccine candidates against TNBC. METHODSː in this research, an efficient novel vaccine against TNBC was designed by using different immunoinformatics and bioinformatics servers. Effective immunodominant epitopes were chosen from three antigenic proteins, containing CEA, MTDH and MUC-1. Recombinant Toll-like Receptor 4 agonists were utilized as an adjuvant to stimulate immune responses. After antigens and adjuvants selection, appropriate linkers are important to generate a recombinant protein. To achieve an excellent 3D model, the best predicted 3D model must be refined and validated. Then, to demonstrate whether the vaccine / TLR4 complex is stable or not, docking analysis and dynamic molecular simulation were performed. RESULTSː immunoinformatics and bioinformatics evaluations of the construct demonstrated that the designed vaccine could be used effectively for therapeutic goals-against triple-negative breast cancer. CONCLUSIONSː After bioinformatics studies, the designed vaccine has an acceptable quality.. Investigating the effectiveness of this vaccine can be confirmed by supplementary studies in vitro and in vivo conditions.
Type of Study: Full Length | Subject: Molecular Immunology & Vaccines

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb